The Peripheral Neuropathic Pain Market is poised for significant growth due to the increasing awareness of the condition, advancements in therapeutic interventions, and the rising global burden of peripheral neuropathies.
DelveInsight’s “Peripheral Neuropathic Pain Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of the Peripheral Neuropathic Pain, historical and forecasted epidemiology as well as the Peripheral Neuropathic Pain market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
Discover Key Insights into the Peripheral Neuropathic Pain Market with DelveInsight’s In-Depth Report @ Peripheral Neuropathic Pain Market Size
Key Takeaways from the Peripheral Neuropathic Pain Market Report
- In November 2024:- Vertex Pharmaceuticals-A Phase 3, Randomized, Double-blind, Placebo- and Active-Controlled Study of the Efficacy and Safety of Suzetrigine in Subjects With Pain Associated With Diabetic Peripheral Neuropathy. The purpose of this study is to evaluate the efficacy, safety, and tolerability of Suzetrigine (SUZ) in participants with pain associated with diabetic peripheral neuropathy (DPN).
- In November 2024:- Afasci Inc.- This is a randomized, double-blind, placebo-controlled, multicenter Phase II study of the efficacy, safety, tolerability, and PK of oral AFA-281 in 300 patients with painful lumbosacral radiculopathy (PLSR). Patients will be randomized in to the placebo group or doses of AFA-281, titrated over 2 weeks to reach planned daily doses for Weeks 3 and 4. Trials will be conducted simultaneously at 3 sites to meet enrollment targets. The primary efficacy endpoint is 24-hour average pain score based on the 0-10-point Numeric Pain Rating Scale (NPRS) and key secondary endpoint is Oswestry Disability Index (ODI), rates of adverse events, and PK, among others.
- In 2023, the United States recorded the highest incidence of PNP among the 7MM, with ~35,200,000 reported cases.
- The 7MM saw the highest number of severe cases in post-operative and post-traumatic PNP, while moderate cases predominated in PHN in terms of severity.
- Estimates indicate that in 2023, the EU4 and the UK collectively reported approximately 19.3 million cases, with Germany representing the largest share at around 35% of the total cases.
- In 2023, diabetic peripheral neuropathy (DPN) accounted for the highest number of cases in the US, comprising approximately 50% of the total cases.
- The leading Peripheral Neuropathic Pain Companies such as Helixmith, WEX Pharmaceuticals Inc., Lexicon Pharmaceuticals Inc., Bayer, AlzeCure Pharma, Grünenthal, Mallinckrodt Pharmaceuticals., Pfizer, Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., and others
- Promising Peripheral Neuropathic Pain Therapies such as ENGENSIS/VM202 (donaperminogene seltoplasmid), Halneuron, LX9211, BAY2395840, ACD440 gel, and others
Stay ahead in the Peripheral Neuropathic Pain Therapeutics Market with DelveInsight’s Strategic Report @ Peripheral Neuropathic Pain Market Outlook
Peripheral Neuropathic Pain Epidemiology Segmentation in the 7MM
- Total Cases of Peripheral Neuropathic Pain
- Type-specific Cases of Peripheral Neuropathic Pain
- Treated Cases of Peripheral Neuropathic Pain
Download the report to understand which factors are driving Peripheral Neuropathic Pain Epidemiology trends @ Peripheral Neuropathic Pain Prevalence
Marketed Peripheral Neuropathic Pain Drugs
- QUTENZA (capsaicin): Grünenthal and Averitas Pharma
QUTENZA (capsaicin) 8% topical system, a non-systemic, non-opioid pain relief delivered in the form of a patch, indicated for treating neuropathic pain associated with postherpetic neuralgia or associated with diabetic peripheral neuropathy (DPN) of the feet in adults. Capsaicin is an agonist for the transient receptor potential vanilloid 1 receptor (TRPV1), an ion channel-receptor complex expressed on nociceptive nerve fibers in the skin. QUTENZA is marketed and distributed by Averitas. Currently, it is being evaluated under a Phase III trial in post-surgical neuropathic pain. The trial is expected to be completed by October 2024, with an estimated enrollment of 408 participants.
- ZTLIDO (lidocaine): Scilex Pharmaceuticals
ZTLIDO is a topical lidocaine system (1.8%) approved for relieving pain associated with postherpetic neuralgia. ZTLIDO is designed as a lighter, thinner product with improved adhesion relative to LIDODERM (lidocaine patch 5%) while providing a bioequivalent delivery of lidocaine in an efficient drug delivery system. Lidocaine is a local amide anesthetic; it blocks sodium ion channels required for initiating and conducting neuronal impulses.
Emerging Peripheral neuropathic pain Drugs
- SEMDEXA (SP-102): Scilex Holding Company
SP-102 is a preservative-free, surfactant-free, and particulate-free, novel epidural steroid injection (ESI) formulation of 10 mg dexamethasone sodium phosphate in a viscous gel solution for subacute lumbosacral radicular pain (Sciatica). Its extended local effect provides durable pain relief and significant improvement in functioning from a single injection with rapid onset.
- Adezunap (AP707): Apurano Pharmaceuticals
Apurano Pharmaceuticals’ investigational drug AP707, featuring the THC-focused active ingredient adezunap, has received EMA approval for DISCOVER approval studies. Utilizing the patented PuranoTec manufacturing process, cannabis flower undergoes processing to create an aqueous nanodispersion of cannabinoids, primarily ?-9-THC. Administered as a sublingual mouth spray, this dispersion allows for rapid and efficient absorption through the oral mucosa, facilitated by a water-soluble shell termed the smart coating. These SmartLipids, encapsulating lipophilic cannabinoids, remain stable in aqueous environments and can directly enter the bloodstream due to their small particle size (
Get In-Depth Knowledge on Peripheral Neuropathic Pain Market Trends and Forecasts with DelveInsight @ Peripheral Neuropathic Pain Treatment Market
Peripheral Neuropathic Pain Market Outlook
Peripheral Neuropathic Pain Companies, such as Scilex Holding Company, Grünenthal and Averitas Pharma, Eli Lilly and Company, Mitsubishi Tanabe Pharma Corporation, AstraZeneca, Asahi Kasei Pharma, Veloxis Pharmaceuticals, and others, are evaluating their lead candidates in different stages of clinical development, respectively. They aim to investigate their products for the treatment of Peripheral Neuropathic Pain.
Scope of the Peripheral Neuropathic Pain Market Report
- Study Period: 2020–2034
- Coverage: 7MM
- Peripheral Neuropathic Pain Companies: Helixmith, WEX Pharmaceuticals Inc., Lexicon Pharmaceuticals Inc., Bayer, AlzeCure Pharma, Grünenthal, Mallinckrodt Pharmaceuticals., Pfizer, Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., and others
- Peripheral Neuropathic Pain Therapies: ENGENSIS/VM202 (donaperminogene seltoplasmid), Halneuron, LX9211, BAY2395840, ACD440 gel, and others
- Peripheral Neuropathic Pain Therapeutic Assessment: Peripheral Neuropathic Pain current marketed and Peripheral Neuropathic Pain emerging therapies
Unlock Strategic Insights with DelveInsight’s Comprehensive Peripheral Neuropathic Pain Market Report @ Peripheral Neuropathic Pain Market Drivers and Barriers
Table of Content
1. Peripheral Neuropathic Pain Market Report Introduction
2. Executive Summary for Peripheral Neuropathic Pain
3. SWOT analysis of Peripheral Neuropathic Pain
4. Peripheral Neuropathic Pain Patient Share (%) Overview at a Glance
5. Peripheral Neuropathic Pain Market Overview at a Glance
6. Peripheral Neuropathic Pain Disease Background and Overview
7. Peripheral Neuropathic Pain Epidemiology and Patient Population
8. Country-Specific Patient Population of Peripheral Neuropathic Pain
9. Peripheral Neuropathic Pain Current Treatment and Medical Practices
10. Peripheral Neuropathic Pain Unmet Needs
11. Peripheral Neuropathic Pain Emerging Therapies
12. Peripheral Neuropathic Pain Market Outlook
13. Country-Wise Peripheral Neuropathic Pain Market Analysis (2020–2034)
14. Peripheral Neuropathic Pain Market Access and Reimbursement of Therapies
15. Peripheral Neuropathic Pain Market Drivers
16. Peripheral Neuropathic Pain Market Barriers
17. Peripheral Neuropathic Pain Appendix
18. Peripheral Neuropathic Pain Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: yash bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/